Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.55 |
| ▸ | CALML3 | P27482 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SDHA | P31040 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6612901 | 1.00 | MAOA (0.55) | MAOACALML3CYP3A4CYP2D6MAOB | |
| SCHEMBL6791790 | 0.88 | MAOA (0.64) | MAOACALML3CYP3A4MAOBLMNA | |
| SCHEMBL6612909 | 0.87 | CALML3 (0.51) | MAOACALML3CYP3A4CYP2D6MAOB | |
| SCHEMBL8484607 | 0.86 | MAOA (0.66) | MAOACALML3CYP3A4CYP2D6MAOB | |
| SCHEMBL7949645 | 0.86 | MAOA (0.66) | MAOACALML3CYP3A4CYP2D6MAOB | |
| SCHEMBL1393667 | 0.85 | MAOA (0.54) | MAOACALML3CYP3A4CYP2D6MAOB | |
| SCHEMBL6796433 | 0.85 | MAOA (0.61) | MAOACALML3CYP3A4MAOBLMNA | |
| SCHEMBL6612431 | 0.85 | MAOA (0.61) | MAOACALML3CYP3A4MAOBLMNA | |
| SCHEMBL6613809 | 0.85 | MAOA (0.64) | MAOACALML3CYP3A4MAOBLMNA | |
| SCHEMBL6613234 | 0.84 | MAOA (0.60) | MAOACALML3CYP3A4MAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. | 2022-01-13 | — | — | US | disclosed |
| US-11129813-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200397758-A1 | Antimitotic Amides for the Treatment of Cancer and Proliferative Disorders | FROST BIOLOGIC, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10772872-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10016398-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016398-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| WO-2015127284-A2 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | CCNA1, CCNE1, CCNB1 | MAOA 3235/4885CALML3 2787/4885CYP3A4 3673/4885 |
| US-10016398-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | MAOA 3235/4885CALML3 2787/4885CYP3A4 3673/4885 |
| US-11129813-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | MAOA 3235/4885CALML3 2787/4885CYP3A4 3673/4885 |
| US-10772872-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | MAOA 3235/4885CALML3 2787/4885CYP3A4 3673/4885 |
| US-20200397758-A1 | Antimitotic Amides for the Treatment of Cancer and Proliferative Disorders | CCNA1, CCNE1, CCNB1 | MAOA 3235/4885CALML3 2787/4885CYP3A4 3673/4885 |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | CCNA1, CCNE1, CCNB1 | MAOA 3235/4885CALML3 2787/4885CYP3A4 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.